Amitriptyline plasma levels and clinical response in primary depression

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Neuroscience

Background:

• Primary depression is a complex mood disorder requiring effective treatment strategies.
• Antidepressant medication efficacy can be influenced by patient-specific pharmacokinetic factors.

Purpose of the Study:

• To investigate the correlation between plasma levels of amitriptyline and its metabolite, nortriptyline, and clinical improvement in patients with primary depression.
• To determine if plasma tricyclic levels can predict treatment response.

Main Methods:

• A 4-week double-blind, placebo-controlled study involving 16 patients with primary depression.
• Hamilton Depression Rating Scale (HDRS) was used to assess clinical status by blinded raters.
• Plasma levels of amitriptyline (AT) and nortriptyline (NT) were measured twice weekly using gas chromatography-mass spectrometry.

Main Results:

• A significant negative correlation was observed between the Hamilton Score and mean total tricyclic plasma levels (p < 0.01).
• Mean total tricyclic (AT + NT) plasma levels effectively discriminated between clinical responders and nonresponders by day 12 (p < 0.001).
• An arbitrary threshold of 200 ng/ml total tricyclic plasma level correctly classified 88% of patients by day 26.

Conclusions:

• Plasma levels of amitriptyline and nortriptyline are positively correlated with clinical improvement in primary depression.
• Therapeutic drug monitoring of tricyclic antidepressant plasma levels may optimize treatment outcomes.
• Establishing optimal plasma concentration ranges can enhance the effectiveness of antidepressant therapy.